Skip to main content
Fig. 1 | Trials

Fig. 1

From: Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial

Fig. 1

Schematic chart of the process of the clinical trial. Abbreviations: ABC1 Autism Behavior Checklist, ABC2 Aberrant Behavior Checklist, ACER Average cost-effectiveness ratio, ACUR Average cost-utility ratio, AE Adverse event, ANCOVA Analysis of covariance, ASD Autism spectrum disorder, CARS Childhood Autism Rating Scale, CBA Cost-benefit analysis, CEA Cost-effectiveness analysis, CHQ-PF28 Child Health Questionnaire-Parent Report Form 28, CUA Cost-utility analysis, EQ-5D-Y EuroQoL Five-dimension Five-level Youth, FAS Full analysis set, ICER Incremental cost-effectiveness ratio, IRB Institutional review board, K-CTC Korean Medicine Clinical Trial Center, K-PSI-SF Korean Parenting Stress Index Short Form, PDD Pervasive developmental disorder, PPS Per protocol set, PSI Parenting Stress Index, RCT Randomized controlled trial, SAS Safety Assessment Set, SMS Social Maturity Scale, TCM Traditional Chinese Medicine,UGSJB Ukgansangajinpibanha

Back to article page